{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T08:03:08Z","timestamp":1774080188185,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10072-025-08793-5","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:08:13Z","timestamp":1772078893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety profile of tofersen in amyotrophic lateral sclerosis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"given":"Francisco Jos\u00e9","family":"Tarazona-Santabalbina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"Belenguer-Varea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Borr\u00e1s-Blasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Garc\u00eda-Tercero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena Linge","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi Perez","family":"Prior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Mariscal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-9877","authenticated-orcid":false,"given":"Alejandro","family":"Valcuende-Rosique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"8793_CR1","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1055\/a-1562-7882","volume":"146","author":"T Meyer","year":"2021","unstructured":"Meyer T (2021) Amyotrophe lateralsklerose (ALS) \u2013 Diagnose, Verlauf und neue behandlungsoptionen. Dtsch Med Wochenschr 146:1613\u20131618. https:\/\/doi.org\/10.1055\/a-1562-7882","journal-title":"Dtsch Med Wochenschr"},{"key":"8793_CR2","doi-asserted-by":"publisher","first-page":"e613","DOI":"10.1212\/WNL.0000000000207474","volume":"101","author":"C Wolfson","year":"2023","unstructured":"Wolfson C, Gauvin DE, Ishola F, Oskoui M (2023) Global prevalence and incidence of amyotrophic lateral sclerosis: a systematic review. Neurology 101:e613\u2013e623. https:\/\/doi.org\/10.1212\/WNL.0000000000207474","journal-title":"Neurology"},{"key":"8793_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12916-022-02411-3","volume":"20","author":"WM Su","year":"2022","unstructured":"Su WM, Gu XJ, Duan QQ et al (2022) Genetic factors for survival in amyotrophic lateral sclerosis: an integrated approach combining a systematic review, pairwise and network meta-analysis. BMC Med 20:209. https:\/\/doi.org\/10.1186\/s12916-022-02411-3","journal-title":"BMC Med"},{"key":"8793_CR4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/jnnp-2016-315018","volume":"88","author":"ZY Zou","year":"2017","unstructured":"Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP (2017) Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 88:540\u2013549. https:\/\/doi.org\/10.1136\/jnnp-2016-315018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8793_CR5","first-page":"592","volume":"56","author":"A Pramatarova","year":"1995","unstructured":"Pramatarova A, Figlewicz DA, Krizus A et al (1995) Identification of new mutations in the Cu\/Zn superoxide dismutase gene of patients with Familial amyotrophic lateral sclerosis. Am J Hum Genet 56:592\u2013596","journal-title":"Am J Hum Genet"},{"key":"8793_CR6","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1007\/s00415-024-12437-7","volume":"271","author":"M Sabatelli","year":"2024","unstructured":"Sabatelli M, Cerri F, Zuccarino R et al (2024) Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patients. J Neurol 271:5177\u20135186. https:\/\/doi.org\/10.1007\/s00415-024-12437-7","journal-title":"J Neurol"},{"key":"8793_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/mus.28182","volume":"70","author":"T Meyer","year":"2024","unstructured":"Meyer T, Schumann P, Weydt P et al (2024) Clinical and patient-reported outcomes and neurofilament response during Tofersen treatment in SOD1-related ALS\u2014A multicenter observational study over 18 months. Muscle Nerve 70:333\u2013345. https:\/\/doi.org\/10.1002\/mus.28182","journal-title":"Muscle Nerve"},{"key":"8793_CR8","first-page":"24044","volume":"121","author":"K Forsberg","year":"2024","unstructured":"Forsberg K, Karlsborg M, Salvesen L et al (2024) SOD1 gene therapy delays ALS disease progression. Lakartidningen 121:24044","journal-title":"Lakartidningen"},{"key":"8793_CR9","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair HA (2023) Tofersen: first approval. Drugs 83:1039\u20131043. https:\/\/doi.org\/10.1007\/s40265-023-01904-6","journal-title":"Drugs"},{"key":"8793_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/17582024.2024.2421738","volume":"14","author":"MC Virata","year":"2024","unstructured":"Virata MC, Catahay JA, Lippi G, Henry BM (2024) Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies. Neurodegener Dis Manag 14:227\u2013239. https:\/\/doi.org\/10.1080\/17582024.2024.2421738","journal-title":"Neurodegener Dis Manag"},{"key":"8793_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s42466-023-00305-0","volume":"6","author":"M Vidovic","year":"2024","unstructured":"Vidovic M, Menschikowski M, Freigang M et al (2024) Macrophage inclusions in cerebrospinal fluid following treatment initiation with antisense oligonucleotide therapies in motor neuron diseases. Neurol Res Pract 6:11. https:\/\/doi.org\/10.1186\/s42466-023-00305-0","journal-title":"Neurol Res Pract"},{"key":"8793_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller T, Cudkowicz M, Shaw PJ et al (2020) Phase 1\u20132 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 383:109\u2013119. https:\/\/doi.org\/10.1056\/NEJMoa2003715","journal-title":"N Engl J Med"},{"key":"8793_CR13","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A et al (2022) Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 387:1099\u20131110. https:\/\/doi.org\/10.1056\/NEJMoa2204705","journal-title":"N Engl J Med"},{"key":"8793_CR14","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s10072-025-07994-2","volume":"46","author":"AA Hamad","year":"2025","unstructured":"Hamad AA, Alkhawaldeh IM, Nashwan AJ et al (2025) Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci 46:1977\u20131985. https:\/\/doi.org\/10.1007\/s10072-025-07994-2","journal-title":"Neurol Sci"},{"key":"8793_CR15","doi-asserted-by":"publisher","first-page":"102495","DOI":"10.1016\/j.eclinm.2024.102495","volume":"69","author":"M Wiesenfarth","year":"2024","unstructured":"Wiesenfarth M, Dorst J, Brenner D et al (2024) Effects of Tofersen treatment in patients with SOD1-ALS in a real-world setting \u2013 a 12-month multicenter cohort study from the German early access program. EClinicalMedicine 69:102495. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102495","journal-title":"EClinicalMedicine"},{"key":"8793_CR16","doi-asserted-by":"publisher","first-page":"11034","DOI":"10.1038\/s41598-025-94984-1","volume":"15","author":"C Simonini","year":"2025","unstructured":"Simonini C, Zucchi E, Martinelli I et al (2025) Neurodegenerative and neuroinflammatory changes in SOD1-ALS patients receiving Tofersen. Sci Rep 15:11034. https:\/\/doi.org\/10.1038\/s41598-025-94984-1","journal-title":"Sci Rep"},{"key":"8793_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/acn3.52264","volume":"12","author":"SE Smith","year":"2025","unstructured":"Smith SE, McCoy-Gross K, Malcolm A et al (2025) Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a real-world setting. Ann Clin Transl Neurol 12:311\u2013319. https:\/\/doi.org\/10.1002\/acn3.52264","journal-title":"Ann Clin Transl Neurol"},{"key":"8793_CR18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"8793_CR19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D et al (2003) Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 73:712\u2013716. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x","journal-title":"ANZ J Surg"},{"key":"8793_CR20","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10:ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142","journal-title":"Cochrane Database Syst Rev"},{"key":"8793_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","volume":"66","author":"GH Guyatt","year":"2013","unstructured":"Guyatt GH, Thorlund K, Oxman AD et al (2013) GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles\u2013continuous outcomes. J Clin Epidemiol 66:173\u2013183. https:\/\/doi.org\/10.1016\/j.jclinepi.2012.08.001","journal-title":"J Clin Epidemiol"},{"key":"8793_CR22","unstructured":"Spanish Agency for Medicines and Health Products (AEMPS) (2025) Summary of product characteristics: Qalsody 100\u00a0mg solution for injection. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1231783001\/FT_1231783001.html. Accessed 25 Sept 2025"},{"key":"8793_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.neurol.2017.03.031","volume":"173","author":"MH Soriani","year":"2017","unstructured":"Soriani MH, Desnuelle C (2017) Care management in amyotrophic lateral sclerosis. Rev Neurol (Paris) 173:288\u2013299. https:\/\/doi.org\/10.1016\/j.neurol.2017.03.031","journal-title":"Rev Neurol (Paris)"},{"key":"8793_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1017\/cjn.2020.240","volume":"48","author":"M Munan","year":"2021","unstructured":"Munan M, Luth W, Genuis SK, Johnston WSW, MacIntyre E (2021) Transitions in amyotrophic lateral sclerosis: patient and caregiver experiences. Can J Neurol Sci 48:496\u2013503. https:\/\/doi.org\/10.1017\/cjn.2020.240","journal-title":"Can J Neurol Sci"},{"key":"8793_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41582-023-00867-2","volume":"19","author":"SA Goutman","year":"2023","unstructured":"Goutman SA, Savelieff MG, Jang DG, Hur J, Feldman EL (2023) The amyotrophic lateral sclerosis exposome: recent advances and future directions. Nat Rev Neurol 19:617\u2013634. https:\/\/doi.org\/10.1038\/s41582-023-00867-2","journal-title":"Nat Rev Neurol"},{"key":"8793_CR26","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1007\/s00415-024-12435-9","volume":"271","author":"N Riva","year":"2024","unstructured":"Riva N, Domi T, Pozzi L et al (2024) Update on recent advances in amyotrophic lateral sclerosis. J Neurol 271:4693\u20134723. https:\/\/doi.org\/10.1007\/s00415-024-12435-9","journal-title":"J Neurol"},{"key":"8793_CR27","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1007\/s00415-023-12130-1","volume":"271","author":"P Reilich","year":"2024","unstructured":"Reilich P, Sch\u00f6berl F, Hiebeler M, Tonon M, Ludolph AC, Senel M (2024) Myelitis as a side effect of Tofersen therapy in SOD1-associated ALS. J Neurol 271:2114\u20132118. https:\/\/doi.org\/10.1007\/s00415-023-12130-1","journal-title":"J Neurol"},{"key":"8793_CR28","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/mus.28372","volume":"71","author":"A Lovett","year":"2025","unstructured":"Lovett A, Chary S, Babu S et al (2025) Serious neurologic adverse events in Tofersen clinical trials for amyotrophic lateral sclerosis. Muscle Nerve 71:1006\u20131015. https:\/\/doi.org\/10.1002\/mus.28372","journal-title":"Muscle Nerve"},{"key":"8793_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/17582024.2024.2402216","volume":"14","author":"WH Everett","year":"2024","unstructured":"Everett WH, Bucelli RC (2024) Tofersen for SOD1 ALS. Neurodegener Dis Manag 14:149\u2013160. https:\/\/doi.org\/10.1080\/17582024.2024.2402216","journal-title":"Neurodegener Dis Manag"},{"key":"8793_CR30","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s40263-025-01204-5","volume":"39","author":"A McGuigan","year":"2025","unstructured":"McGuigan A, Blair HA (2025) Tofersen: a review in amyotrophic lateral sclerosis associated with SOD1 mutations. CNS Drugs 39:903\u2013912. https:\/\/doi.org\/10.1007\/s40263-025-01204-5","journal-title":"CNS Drugs"},{"key":"8793_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15661","author":"JF V\u00e1zquez-Costa","year":"2022","unstructured":"V\u00e1zquez-Costa JF, Borrego-Hern\u00e1ndez D, Paradas C et al (2022) Characterizing SOD1 mutations in spain: the impact of genotype, age, and sex in the natural history of the disease. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15661","journal-title":"Eur J Neurol"},{"key":"8793_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-3-030-78787-5_16","volume":"1339","author":"K Kadena","year":"2021","unstructured":"Kadena K, Vlamos P (2021) The importance of diagnostic and prognostic biomarker identification and classification towards Understanding ALS pathogenesis. Adv Exp Med Biol 1339:119\u2013120. https:\/\/doi.org\/10.1007\/978-3-030-78787-5_16","journal-title":"Adv Exp Med Biol"},{"key":"8793_CR33","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1474-4422(24)00259-X","volume":"23","author":"M Haberkamp","year":"2024","unstructured":"Haberkamp M, Aislaitner G, Mart\u00ednez-Lapiscina EH, Weise M (2024) Tofersen for SOD1-associated amyotrophic lateral sclerosis. Lancet Neurol 23:772\u2013773. https:\/\/doi.org\/10.1016\/S1474-4422(24)00259-X","journal-title":"Lancet Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08793-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08793-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08793-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:36:06Z","timestamp":1774074966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08793-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["8793"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08793-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"292"}}